Mesenchymal stromal/stem cells (MSCs) are a promising therapeutic agent for various diseases, including sepsis. However, translating MSC therapy to clinical applications remains challenging due to variations in the properties of MSCs under different preparation conditions. In this study, the gene expression profiles of human adipose-derived mesenchymal stromal/stem cells (ADSCs) under different culture conditions were compared in relation to their therapeutic efficacy for sepsis. Results showed that ADSCs cultured in media supplemented with human platelet lysates (hPL) (hPL-ADSCs) exhibited a smaller cell size and higher proliferative capacity, whereas ADSCs cultured in media supplemented with fetal bovine serum (FBS) (FBS-ADSCs) showed a broader and flatter shape. Both hPL-ADSCs and FBS-ADSCs exhibited a protective effect in a mouse model of sepsis; however, hPL-ADSCs displayed a better potency for immunosuppressive function, as evidenced by a better improvement of survival rate and further reduction of tissue injury and infectious biomarkers (alanine transaminase and procalcitonin). Furthermore, hPL-ADSCs caused a more anti-inflammatory transcriptomic shift, whereas FBS-ADSCs led to more depression of proinflammatory transcriptomic response. This study thus demonstrates that both hPL-ADSCs and FBS-ADSCs are effective for antiseptic therapy via different mechanisms of inflammatory manipulation, although hPL-ADSCs may imply a better preference.
Get full access to this article
View all access options for this article.
References
1.
KeaneC, JerkicM and LaffeyJG. (2017). Stem cell-based therapies for sepsis. Anesthesiology, 127:1017–1034.
2.
OuH, ZhaoS, PengY, XiaoX, WangQ, LiuH, XiaoX and YangM. (2016). Comparison of bone marrow tissue- and adipose tissue-derived mesenchymal stem cells in the treatment of sepsis in a murine model of lipopolysaccharide-induced sepsis. Mol Med Rep, 14:3862–3870.
3.
LeeJY, KangMH, JangJE, LeeJE, YangY, ChoiJY, KangHS, LeeU, ChoungJW, et al. (2022). Comparative analysis of mesenchymal stem cells cultivated in serum free media. Sci Rep, 12:8620.
4.
VarkouhiAK, HeX, Teixeira MonteiroAP, AmatullahH, TsoporisJN, GuptaS, EktesabiAM, MeiSHJ, StewartDJ, KeatingA and Dos SantosCC. (2021). Immunophenotypic characterization and therapeutics effects of human bone marrow- and umbilical cord-derived mesenchymal stromal cells in an experimental model of sepsis. Exp Cell Res, 399:112473.
5.
HalmeDG and KesslerDA. (2006). FDA regulation of stem-cell-based therapies. N Engl J Med, 355:1730–1735.
6.
BurnoufT, StrunkD, KohMB and SchallmoserK. (2016). Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation?. Biomaterials, 76:371–387.
7.
MirabetV, SolvesP, MinanaMD, EncaboA, Carbonell-UberosF, BlanquerA and RoigR. (2008). Human platelet lysate enhances the proliferative activity of cultured human fibroblast-like cells from different tissues. Cell Tissue Bank, 9:1–10.
8.
GriffithsS, BaraniakPR, CoplandIB, NeremRM and McDevittTC. (2013). Human platelet lysate stimulates high-passage and senescent human multipotent mesenchymal stromal cell growth and rejuvenation in vitro. Cytotherapy, 15:1469–1483.
9.
GuiottoM, RaffoulW, HartAM, RiehleMO and di SummaPG. (2020). Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review. J Transl Med, 18:351.
10.
LiaoG, LiaoY, LiD, FuZ, WuS, ChengD, OuyangQ, TangZ, ZengG, et al. (2021). Human platelet lysate maintains stemness of umbilical cord-derived mesenchymal stromal cells and promote lung repair in rat bronchopulmonary dysplasia. Front Cell Dev Biol, 9:722953.
11.
KimK, ThorpH, Bou-GhannamS, GraingerDW and OkanoT. (2020). Stable cell adhesion affects mesenchymal stem cell sheet fabrication: effects of fetal bovine serum and human platelet lysate. J Tissue Eng Regen Med, 14:741–753.
12.
FlemmingA, SchallmoserK, StrunkD, StolkM, VolkHD and SeifertM. (2011). Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate. J Clin Immunol, 31:1143–1156.
13.
BiebackK, HeckerA, KocaomerA, LannertH, SchallmoserK, StrunkD and KluterH. (2009). Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells, 27:2331–2341.
14.
AbdelrazikH, SpaggiariGM, ChiossoneL and MorettaL. (2011). Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol, 41:3281–3290.
15.
CecconiM, EvansL, LevyM and RhodesA. (2018). Sepsis and septic shock. Lancet (London, England), 392:75–87.
16.
ChoustermanBG, SwirskiFK and WeberGF. (2017). Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol, 39:517–528.
17.
FinferS and MachadoFR. (2016). The global epidemiology of sepsis. Does it matter that we know so little? Am J Respir Crit Care Med, 193:228–230.
18.
PernerA, GordonAC, De BackerD, DimopoulosG, RussellJA, LipmanJ, JensenJU, MyburghJ, SingerM, BellomoR and WalshT. (2016). Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Med, 42:1958–1969.
19.
HallSR, TsoyiK, IthB, PaderaRFJr., LedererJA, WangZ, LiuX and PerrellaMA. (2013). Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils. Stem Cells, 31:397–407.
MeiSH, HaitsmaJJ, Dos SantosCC, DengY, LaiPF, SlutskyAS, LilesWC and StewartDJ. (2010). Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med, 182:1047–1057.
24.
AhnSY, MaengYS, KimYR, ChoeYH, HwangHS and HyunYM. (2020). In vivo monitoring of dynamic interaction between neutrophil and human umbilical cord blood-derived mesenchymal stem cell in mouse liver during sepsis. Stem Cell Res Ther, 11:44.
25.
ShrumB, AnanthaRV, XuSX, DonnellyM, HaeryfarSM, McCormickJK and MeleT. (2014). A robust scoring system to evaluate sepsis severity in an animal model. BMC Res Notes, 7:233.
26.
SilvaJD, Lopes-PachecoM, de CastroLL, KitokoJZ, TrivelinSA, AmorimNR, CapelozziVL, MoralesMM, GutfilenB, et al. (2019). Eicosapentaenoic acid potentiates the therapeutic effects of adipose tissue-derived mesenchymal stromal cells on lung and distal organ injury in experimental sepsis. Stem Cell Res Ther, 10:264.
27.
van der ValkJ. (2022). Fetal bovine serum-a cell culture dilemma. Science, 375:143–144.
28.
ShanskyYD, SergeevaNS, SviridovaIK, KaralkinPA, KirsanovaVA, AkhmedovaSA, FomichevaKA, ShkurnikovMY, PortyannikovaAY and KaprinAD. (2019). Human platelet lysate sustains the osteogenic/adipogenic differentiation potential of adipose-derived mesenchymal stromal cells and maintains their DNA integrity in vitro. Cells Tissues Organs, 207:149–164.
29.
WuRX, YuY, YinY, ZhangXY, GaoLN and ChenFM. (2017). Platelet lysate supports the in vitro expansion of human periodontal ligament stem cells for cytotherapeutic use. J Tissue Eng Regen Med, 11:2261–2275.
30.
HoMS, MeiSH and StewartDJ. (2015). The immunomodulatory and therapeutic effects of mesenchymal stromal cells for acute lung injury and sepsis. J Cell Physiol, 230:2606–2617.
31.
KhosrojerdiA, SoudiS, HosseiniAZ, EshghiF, ShafieeA and HashemiSM. (2021). Immunomodulatory and therapeutic effects of mesenchymal stem cells on organ dysfunction in sepsis. Shock, 55:423–440.
32.
SongN, ScholtemeijerM and ShahK. (2020). Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci, 41:653–664.
33.
López-GarcíaL and Castro-ManrrezaME. (2021). TNF-α and IFN-γ participate in improving the immunoregulatory capacity of mesenchymal stem/stromal cells: importance of cell-cell contact and extracellular vesicles. Int J Mol Sci, 22:9531.
34.
MaS, XieN, LiW, YuanB, ShiY and WangY. (2014). Immunobiology of mesenchymal stem cells. Cell Death Differ, 21:216–225.
35.
RaicevicG, RouasR, NajarM, StordeurP, BoufkerHI, BronD, MartiatP, GoldmanM, NevessignskyMT and LagneauxL. (2010). Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum Immunol, 71:235–244.
36.
RenG, ZhangL, ZhaoX, XuG, ZhangY, RobertsAI, ZhaoRC and ShiY. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2:141–150.
37.
LiottaF, AngeliR, CosmiL, FilìL, ManuelliC, FrosaliF, MazzinghiB, MaggiL, PasiniA, et al. (2008). Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells, 26:279–289.
38.
PezzaniteLM, ChowL, JohnsonV, GriffenhagenGM, GoodrichL and DowS. (2021). Toll-like receptor activation of equine mesenchymal stromal cells to enhance antibacterial activity and immunomodulatory cytokine secretion. Vet Surg, 50:858–871.
39.
Du-RocherB, BinatoR, de-Freitas-JuniorJCM, CorreaS, MencalhaAL, Morgado-DiazJA and AbdelhayE. (2020). IL-17 triggers invasive and migratory properties in human MSCs, while IFNy favors their immunosuppressive capabilities: implications for the “licensing” process. Stem Cell Rev Rep, 16:1266–1279.
40.
LuS and QiaoX. (2021). Single-cell profiles of human bone marrow-derived mesenchymal stromal cells after IFN-γ and TNF-α licensing. Gene, 771:145347.
41.
BaiX, XiJ, BiY, ZhaoX, BingW, MengX, LiuY, ZhuZ and SongG. (2017). TNF-α promotes survival and migration of MSCs under oxidative stress via NF-κB pathway to attenuate intimal hyperplasia in vein grafts. J Cell Mol Med, 21:2077–2091.
42.
PierrakosC, VelissarisD, BisdorffM, MarshallJC and VincentJL. (2020). Biomarkers of sepsis: time for a reappraisal. Crit Care, 24:287.
43.
SchulteW, BernhagenJ and BucalaR. (2013). Cytokines in sepsis: potent immunoregulators and potential therapeutic targets—an updated view. Mediators Inflamm, 2013:165974.
44.
BernardoME and FibbeWE. (2013). Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell, 13:392–402.
45.
WenM, CaiG, YeJ, LiuX, DingH and ZengH. (2020). Single-cell transcriptomics reveals the alteration of peripheral blood mononuclear cells driven by sepsis. Ann Transl Med, 8:125.
46.
XieX, ShiQ, WuP, ZhangX, KambaraH, SuJ, YuH, ParkSY, GuoR, et al. (2020). Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. Nat Immunol, 21:1119–1133.
47.
JanskýL, ReymanováP and KopeckýJ. (2003). Dynamics of cytokine production in human peripheral blood mononuclear cells stimulated by LPS or infected by Borrelia. Physiol Res, 52:593–598.
48.
FengB, ZhuJ, XuY, ChenW, ShengX, FengX, ShiX, LiuJ, PanQ, et al. (2020). Immunosuppressive effects of mesenchymal stem cells on lung B cell gene expression in LPS-induced acute lung injury. Stem Cell Res Ther, 11:418.
49.
ZhuJ, FengB, XuY, ChenW, ShengX, FengX, ShiX, LiuJ, PanQ, et al. (2020). Mesenchymal stem cells alleviate LPS-induced acute lung injury by inhibiting the proinflammatory function of Ly6C(+) CD8(+) T cells. Cell Death Dis, 11:829.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
